Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01934712
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1862
- Registration Number
- NCT01934686
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1668
- Registration Number
- NCT01934673
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: insulin 338 (GIPET I)
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT01931137
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1231
- Registration Number
- NCT01930188
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhia, Ukraine
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT01927861
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Zentsuji, Kagawa, Japan
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01924637
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: oral placebo
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 632
- Registration Number
- NCT01923181
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 343
- Registration Number
- NCT01917656
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2HealthyDiabetes
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT01916174
© Copyright 2025. All Rights Reserved by MedPath